<DOC>
	<DOCNO>NCT00832364</DOCNO>
	<brief_summary>The purpose study assess safety efficacy injectable biologic U0279 combination therapy compare injectable biologic alone severe plaque-type psoriasis .</brief_summary>
	<brief_title>Trial Injectable Biologic U0279 Combination Therapy Severe Plaque-Type Psoriasis</brief_title>
	<detailed_description>The study conduct order obtain safety efficacy data injectable biologic U0279 combination therapy compare injectable biologic alone severe plaque-type psoriasis . The subject randomize either U0279 placebo injectable biologic 12 week previously . The subject study medication 12 week . The subject must moderate severe Psoriasis</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male female subject 18 year age old . Surgically sterile female . Females hysterectomy complete menopause allow . Affected Body Surface Area psoriasis ≥10 % . Psoriasis Global Assessment rating `` moderate severe '' `` severe '' . Achieved mild moderate improvement receive injectable biologic therapy least 12 week . A PASI score ≥ 50 ≤75 Capable understand willing provide sign dated write voluntary inform consent ( local national authorization requirement ) protocol specific procedure perform Understand sponsor pay injectable biologic therapy course study ; willing pay pocket secure payment private health insurance injectable biologic . History systemic infection , condition may interfere study evaluation may increase risk participation . , tuberculosis , human immunodeficiency virus ( HIV ) , hepatitis ; congestive heart failure demyelinate disorder . Used prohibited medication therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Moderate Severe Plaque Psoriasis</keyword>
</DOC>